A detailed history of Dimensional Fund Advisors LP transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 505,644 shares of ZNTL stock, worth $1.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
505,644
Previous 626,663 19.31%
Holding current value
$1.75 Million
Previous $2.56 Million 27.62%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$2.9 - $4.57 $350,955 - $553,056
-121,019 Reduced 19.31%
505,644 $1.86 Million
Q2 2024

Aug 09, 2024

SELL
$4.09 - $16.13 $396,701 - $1.56 Million
-96,993 Reduced 13.4%
626,663 $2.56 Million
Q1 2024

May 10, 2024

SELL
$10.83 - $16.49 $4,082 - $6,216
-377 Reduced 0.05%
723,656 $11.4 Million
Q4 2023

Feb 07, 2024

BUY
$9.84 - $20.13 $2.36 Million - $4.83 Million
239,714 Added 49.5%
724,033 $11 Million
Q3 2023

Nov 09, 2023

BUY
$19.63 - $28.29 $2.17 Million - $3.12 Million
110,415 Added 29.53%
484,319 $9.72 Million
Q2 2023

Aug 09, 2023

BUY
$17.41 - $30.05 $889,772 - $1.54 Million
51,107 Added 15.83%
373,904 $10.5 Million
Q1 2023

May 12, 2023

BUY
$16.14 - $24.94 $3.06 Million - $4.73 Million
189,766 Added 142.65%
322,797 $5.55 Million
Q4 2022

Feb 09, 2023

BUY
$18.07 - $25.6 $1.78 Million - $2.53 Million
98,683 Added 287.3%
133,031 $2.68 Million
Q3 2022

Nov 10, 2022

SELL
$20.23 - $31.73 $755,833 - $1.19 Million
-37,362 Reduced 52.1%
34,348 $744,000
Q2 2022

Aug 12, 2022

SELL
$17.91 - $52.25 $354,474 - $1.03 Million
-19,792 Reduced 21.63%
71,710 $2.01 Million
Q1 2022

May 13, 2022

BUY
$41.58 - $80.89 $3.8 Million - $7.4 Million
91,502 New
91,502 $4.22 Million

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $198M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.